The GlaxoSmithKline spin-out, which is working on treatments for hearing disorders, has raised additional funds to extend the Pfizer-backed round to $36.6m.
UK-based biotechnology company Autifony Therapeutics has raised £23.5m ($36.6m) in a series A round backed by Pfizer Venture Investments, the corporate venturing arm of pharmaceutical company Pfizer.
Autifony had previously raised more than £15m in the round from Pfizer, healthcare company GlaxoSmithKline (GSK), venture capital firm SV Life Sciences, investment trust International Biotechnology Trust, Imperial Innovations and UCL Business, before closing an £8m extension on Friday.
GSK, SV Life Sciences, Imperial Innovations and UCL Business originally provided £10m in series…
